Antitumor effects of Rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 273-285

  Dai, Zhi Jun ^a   Gao, Jie ^b   Ma, Xiao Bin ^a   Kang, Hua Feng ^a   Wang, Bao Feng ^a   Lu, Wang Feng ^a   Lin, Shuai ^a   Wang, Xi Jing ^a   Wu, Wen Ying ^b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anti tumor; Apoptosis; Autophagy; MTOR; Pancreatic carcinoma; Rapamycin

Indexed keywords

BECLIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN BAX; PROTEIN P53; RAPAMYCIN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; CADAVERINE; DANSYLCADAVERINE; MEMBRANE PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BAX GENE; BECLIN 1 GENE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL VACUOLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; PANCREAS CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR SUPPRESSOR GENE; UPREGULATION; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; CELL SHAPE; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

MAMMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BCL-2-ASSOCIATED X PROTEIN; CADAVERINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; MICE; NIH 3T3 CELLS; PANCREATIC NEOPLASMS; RNA, MESSENGER; SIROLIMUS; TOR SERINE-THREONINE KINASES; VACUOLES;

EID: 84872190720     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14010273     Document Type: Article

References (47)

1. Stathis, A.; Moore, M.J. Advanced pancreatic carcinoma: Current treatment and future challenges. Nat. Rev. Clin. Oncol. 2010, 7, 163-172.
2. Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605-1617.
3. Vincent, A.; Herman, J.; Schulick, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607-620.
4. Morris, R.E. Rapamycin: Antifungal, antitumor, antiproliferative and immunosuppressive macrolide. Transpl. Rev. 1992, 16, 39-45.
5. Svirshchevskaya, E.V.; Mariotti, J.; Wright, M.H.; Viskova, N.Y.; Telford, W.; Fowler, D.H.; Varticovski, L. Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity. BMC Cancer 2008, 8, doi:10.1186/1471-2407-8-176.
6. Wu, Q.; Kiguchi, K.; Kawamoto, T.; Ajiki, T.; Traag, J.; Carbajal, S.; Ruffino, L.; Thames, H.; Wistuba, I.; Thomas, M.; et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007, 67, 3794-3800.
7. Butzal, M.; Loges, S.; Schweizer, M.; Fischer, U.; Gehling, U.M.; Hossfeld, D.K.; Fiedler, W. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp. Cell Res. 2004, 300, 65-71.
8. Morikawa, Y.; Koike, H.; Sekine, Y.; Matsui, H.; Shibata, Y.; Ito, K.; Suzuki, K. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation. Biochem. Biophys. Res. Commun. 2012, 419, 584-589.
9. Li, R.; Wang, R.; Zhai, R.; Dong, Z. Targeted inhibition of mammalian target of rapamycin (mTOR) signaling pathway inhibits proliferation and induces apoptosis of laryngeal carcinoma cells in vitro. Tumori 2011, 97, 781-786.
10. Di Paolo, S.; Teutonico, A.; Ranieri, E.; Gesualdo, L.; Schena, P.F. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am. J. Kidney Dis. 2007, 49, 462-470.
11. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C.J.; Zuelke, C.; Farkas, S.; Anthuber, M.; et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med. 2002, 8, 128-135.
12. Huang, S.; Houghton, P.J. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 2003, 3, 371-377.
13. Asnaghi, L.; Bruno, P.; Priulla, M.; Nicolin, A. mTOR: A protein kinase switching between life and death. Pharmacol. Res. 2004, 50, 545-549.
14. Ito, D.; Fujimoto, K.; Mori, T.; Kami, K.; Koizumi, M.; Toyoda, E.; Kawaguchi, Y.; Doi, R. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer 2006, 118, 2337-2343.
15. Lang, S.A.; Gaumann, A.; Koehl, G.E.; Seidel, U.; Bataille, F.; Klein, D.; Ellis, L.M.; Bolder, U.; Hofstaedter, F.; Schlitt, H.J.; et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer 2007, 120, 1803-1810.
16. Shafer, A.; Zhou, C.; Gehrig, P.A.; Boggess, J.F.; Bae-Jump, V.L. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int. J. Cancer 2010, 126, 1144-1154.
17. Makhlin, I.; Zhang, J.; Long, C.J.; Devarajan, K.; Zhou, Y.; Klein-Szanto, A.J.; Huang, M.; Chernoff, J.; Boorjian, S.A. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int. 2011, 108, E84-E90.
18. Kobayashi, S.; Kishimoto, T.; Kamata, S.; Otsuka, M.; Miyazaki, M.; Ishikura, H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 2007, 98, 726-733.
19. Garrido-Laguna, I.; Tan, A.C.; Uson, M.; Angenendt, M.; Ma, W.W.; Villaroel, M.C.; Zhao, M.; Rajeshkumar, N.V.; Jimeno, A.; Donehower, R.; et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br. J. Cancer 2010, 103, 649-655.
20. Wolpin, B.M.; Hezel, A.F.; Abrams, T.; Blaszkowsky, L.S.; Meyerhardt, J.A.; Chan, J.A.; Enzinger, P.C.; Allen, B.; Clark, J.W.; Ryan, D.P.; et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27, 193-198.
21. Vo, K.; Amarasinghe, B.; Washington, K.; Gonzalez, A.; Berlin, J.; Dang, T.P. Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation. Mol. Cancer 2011, 10, doi:10.1186/1476-4598-10-138.
22. Shen, Y.; Wang, X.; Xia, W.; Wang, C.; Cai, M.; Xie, H.; Zhou, L.; Zheng S. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro. Transplant. Proc. 2008, 40, 1727-1733.
23. Baehrecke, E.H. How death shapes life during development. Nat. Rev. Mol. Cell Biol. 2002, 3, 779-787.
24. Klionsky, D.J. The molecular machinery of autophagy: Unanswered questions. J. Cell Sci. 2005, 118, 7-18.
25. Kondo, Y.; Kondo, S. Autophagy and cancer therapy. Autophagy 2006, 2, 85-90.
26. Yang, C.; Kaushal, V.; Shah, S.V.; Kaushal, G.P. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2008, 294, F777-F787.
27. Morselli, E.; Galluzzi, L.; Kepp, O.; Vicencio, J.M.; Criollo, A.; Maiuri, M.C.; Kroemer, G. Anti-and pro-tumor functions of autophagy. Biochim. Biophys. Acta 2009, 1793, 1524-1532.
28. Liang, X.H.; Jackson, S.; Seaman, M.; Brown, K.; Kempkes, B.; Hibshoosh, H.; Levine, B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402, 672-676.
29. Yue, Z.; Jin, S.; Yang, C.; Levine, A.J.; Heintz, N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. USA 2003, 100, 15077-15082.
30. Zhou, H.; Huang, S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr. Protein Pept. Sci. 2011, 12, 30-42.
31. Liu, J.; Stevens, P.D.; Gao, T. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J. Biol. Chem. 2011, 286, 6510-6520.
32. Garcia-Echeverria, C. Blocking the mTOR pathway: A drug discovery perspective. Biochem. Soc. Trans. 2011, 39, 451-455.
33. Ghayad, S.E.; Bieche, I.; Vendrell, J.A.; Keime, C.; Lidereau, R.; Dumontet, C.; Cohen, P.A. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008, 99, 1992-2003.
34. Dasanu, C.A.; Clark, B.A., 3rd; Alexandrescu, D.T. mTOR-blocking agents in advanced renal cancer: An emerging therapeutic option. Expert Opin. Investig. Drugs 2009, 18, 175-187.
35. Eum, K.H.; Lee, M. Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells. Mol. Cells 2011, 31, 231-238.
36. Biederbick, A.; Kern, H.F.; Elsässer, H.P. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur. J. Cell Biol. 1995, 66, 3-14.
37. Haupt, S.; Berger, M.; Goldberg, Z.; Haupt, Y. Apoptosis-The p53 network. J. Cell Sci. 2003, 116, 4077-4085.
38. Miyake, N.; Chikumi, H.; Takata, M.; Nakamoto, M.; Igishi, T.; Shimizu, E. Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells. Oncol. Rep. 2012, 28, 848-854.
39. Thornborrow, E.C.; Patel, S.; Mastropietro, A.E.; Schwartzfarb, E.M.; Manfredi, J.J. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 2002, 21, 990-999.
40. Wu, X.; Deng, Y. Bax and BH3 domain only proteins in P53 mediated apoptosis. Front. BioSci. 2002, 7, 151-156.
41. Kihara, A.; Kabeya, Y.; Ohsumi, Y.; Yoshimori, T. Beclin-phosphatidylinositol 3-kinase complex functions at the transgolgi network. EMBO Rep. 2001, 2, 330-335.
42. Donohue, T.M., Jr. Autophagy and ethanol-induced liver injury. World J. Gastroenterol. 2009, 15, 1178-1185.
43. Dai, Z.J.; Gao, J.; Ma, X.B.; Yan, K.; Liu, X.X.; Kang, H.F., Ji, Z.Z.; Guan, H.T. Wang, X.J. Up-regulation of hypoxia inducible factor-1á by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells. J. Exp. Clin. Cancer Res. 2012, 31, doi:10.1186/1756-9966-31-28.
44. Ma, G.; Yang, C.L.; Qu, Y.; Wei, H.Y.; Zhang, T.T.; Zhang, N.J. The flavonoid component isorhamnetin in vitro inhibits proliferation and induces apoptosis in Eca-109 cells. Chem. Biol. Interact. 2007, 167, 153-160.
45. Dai, Z.J.; Gao, J.; Ji, Z.Z.; Wang, X.J.; Ren, H.T.; Liu, X.X.; Wu, W.Y.; Kang, H.F.; Guan, H.T. Matrine Induces Apoptosis in Gastric Carcinoma Cells via Alteration of Fas/FasL and Activation of Caspase-3. J. Ethnopharmacol. 2009, 123, 91-96.
46. Zhang, J.Q.; Li, Y.M.; Liu, T.; He, W.T.; Chen, Y.T.; Chen, X. H; Li. X.; Zhou, W.C. Yi, J.F.; Ren, Z.J. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J. Gastroenterol. 2010, 16, 4281-4290.
47. Guan, H.T.; Xue, X.H.; Dai, Z.J.; Wang, X.J.; Li, A.; Qin, Z.Y. Downregulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J. Gastroenterol. 2006, 12, 2901-2907.